Stage (next event)
Catalyst Info & Data Links
TITLE: ATI-1777 for Atopic Dermatitis Phase 2a Readout
(NCT04598269) Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis
WHAT IS THE NEXT CATALYST EVENT?
Phase 2a Readout
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
10-20-2020 Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
Mechanism of Action
MECHANISM OF ACTION
ATI-1777 is an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor. “Soft” JAK inhibitors are designed to provide JAK inhibition at the site of application and be rapidly metabolized in the systemic circulation. Aclaris plans to develop ATI-1777 as an emollient-containing spray formulation. Aclaris is developing ATI-1777 as a potential treatment for moderate to severe atopic dermatitis.
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post